PCI Pharma Services has completed its previously announced acquisition of Sherpa Clinical Packaging as the company looks to expand its clinical services network to California, US.

The companies have not disclosed the deal value.

Located in San Diego, California, Sherpa provides clinical trial materials management services. The company is specialised in flexible and speed-to-market service delivery to support investigational studies conducted globally.

The acquisition represents complementary packaging, labelling, distribution, temperature-controlled storage and returns services.

PCI can also use Sherpa’s facilities to support existing and new customers. The facilities provide primary and secondary packaging services, and are equipped with cold chain and ultra-cold chain technologies.

The addition of San Diego increases the number of locations where PCI’s manufacturing and packaging facilities are present to eight across three continents.

These facilities support medicines with temperature requirements, including a controlled room temperature of between 15°C and 25°C.

“Sherpa’s investments in its capabilities, capacity, and talent have contributed to a successful service model.”

PCI Pharma Services CEO Salim Haffar said: “Sherpa’s investments in its capabilities, capacity, and talent have contributed to a successful service model.

“The integration of the Sherpa business with our global suite of capabilities and strategic locations allows us to continue to provide a best-in-class offering and be an even stronger partner for our customers.”

PCI has been focused on strengthening its clinical trial supply business. In September last year, the company bought Irish firm Millmount Healthcare to have additional commercial and clinical packaging, storage and distribution capacity.

This acquisition was also aimed at mitigating customer Brexit concerns regarding supply chain continuity.

In February this year, PCI followed up with the acquisition of Australian company Pharmaceutical Packaging Professionals (PPP) to secure direct access to the market for early phase clinical studies conducted in Australia.